Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyronaridine + quinacrine + tilorone + vandetanib
- Development stage
- Preclinical
- Lead developer
- Collaborations Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intranasal, Intravenous, Topical, Buccal, Intramuscular, Intra-arterial, Intramedullary, Intrathecal, Intraventricular, Transdermal, Subcutaneous, Intraperitoneal, Enteral, Sublingual, Vaginal, Ophthalmic, Pulmonary, Rectal
01
Overview
Pyronaridine + quinacrine + tilorone + vandetanib is a four-drug small molecule combination therapy being developed by Collaborations Pharmaceuticals for the treatment of COVID-19. This multi-agent approach is designed to inhibit SARS-CoV-2 by targeting both viral and host processes. The combination includes pyronaridine and quinacrine (antimalarials with lysosomotropic properties), tilorone (an antiviral inducer of interferon), and vandetanib (a multi-kinase inhibitor). The rationale for this combination involves modulating lysosomal function and inhibiting host kinases to disrupt viral entry and replication. The development program also identifies a target referred to as 'Pipro'. The drug is currently in the preclinical in-vivo stage of development.
- Other names
- Pyronaridine/Quinacrine/Tilorone/Vandetanib (COVID-19)
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR3 (Vascular endothelial growth factor receptor 3)RBD (SARS-CoV-2 spike receptor-binding domain)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on pyronaridine + quinacrine + tilorone + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyronaridine + quinacrine + tilorone + vandetanib.